Relieves symptoms of depression. ANDA 88262, held by Strides Pharma Intl. Imipramine Hydrochloride.
As of Nov 16, 2026, ANDA 88262 (Imipramine Hydrochloride), held by Strides Pharma Intl, was first approved by FDA on Oct 21, 1983, with 25 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Depression: For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. Childhood Enuresis: May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 21, 1983 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Imipramine Hydrochloride25MG · tablet;oral | Imipramine Hydrochloride | Rx |
| Jun 24, 2025 | Supplement 42Labeling · Standard review | Approved | None posted |
| May 1, 2023 | Supplement 36Labeling · Standard review | Approved | None posted |
| Sep 11, 2014 | Supplement 34Labeling · Standard review | Approved | None posted |
| Feb 20, 2008 | Supplement 32Labeling | Approved | None posted |
| Jun 25, 2007 | Supplement 30Labeling | Approved | None posted |
| Sep 12, 2005 | Supplement 29Labeling | Approved | None posted |
| May 10, 2005 | Supplement 28Labeling | Approved | None posted |
| May 5, 2005 | Supplement 27Labeling | Approved | None posted |
| May 9, 2003 | Supplement 26Labeling | Approved | None posted |
| Aug 27, 1999 | Supplement 23Labeling | Approved | None posted |
| Oct 2, 1997 | Supplement 22Manufacturing | Approved | None posted |
| Mar 25, 1996 | Supplement 21Manufacturing | Approved | None posted |
| Mar 25, 1996 | Supplement 20Manufacturing | Approved | None posted |
| Mar 25, 1996 | Supplement 19Labeling | Approved | None posted |
| Nov 16, 1995 | Supplement 18Labeling | Approved | None posted |
| Nov 10, 1993 | Supplement 17Labeling | Approved | None posted |
| Jan 7, 1991 | Supplement 16Labeling | Approved | None posted |
| Jun 17, 1986 | Supplement 14Manufacturing | Approved | None posted |
| Jun 17, 1986 | Supplement 13Manufacturing | Approved | None posted |
| Jun 29, 1984 | Supplement 9Manufacturing | Approved | None posted |
| Apr 2, 1984 | Supplement 6Manufacturing | Approved | None posted |
| Apr 2, 1984 | Supplement 5Manufacturing | Approved | None posted |
| Dec 16, 1983 | Supplement 3Manufacturing | Approved | None posted |
| Dec 16, 1983 | Supplement 2Manufacturing | Approved | None posted |
| Dec 16, 1983 | Supplement 1Manufacturing | Approved | None posted |
| Oct 21, 1983 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters